A Phase 2, Randomized, Double-Blind, Dose-Ranging, Two-Part, Multi-Center Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout.

Trial Profile

A Phase 2, Randomized, Double-Blind, Dose-Ranging, Two-Part, Multi-Center Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2012

At a glance

  • Drugs Ulodesine (Primary)
  • Indications Gout
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 May 2011 Pooled efficacy analysis results presented at the 12th Annual Congress of the European League Against Rheumatism.
    • 28 May 2011 Pooled tolerability analysis results presented at the 12th Annual Congress of the European League Against Rheumatism.
    • 26 May 2011 Results presented at EULAR-2011 (poster number THU0027).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top